SBIR-STTR Award

Avoidance of Interference from Insulin Preservatives in a Dual-use Catheter for T1D
Award last edited on: 1/11/2017

Sponsored Program
SBIR
Awarding Agency
NIH : NIDDK
Total Award Amount
$224,150
Award Phase
1
Solicitation Topic Code
200
Principal Investigator
W Kenneth Ward

Company Information

Pacific Diabetes Technologies (AKA: PDT)

2828 SW Corbett Avenue Suite 211-A
Portland, OR 97201
   (503) 847-9170
   info@pacificdt.com
   pacificdt.com
Location: Single
Congr. District: 01
County: Multnomah

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2016
Phase I Amount
$224,150
People with Type 1 diabetes (T1D) are at high risk for acute and chronic complications that can be minimized by concurrent use of continuous insulin delivery and continuous glucose monitoring (CGM). However, the use of two percutaneous devices is cumbersome and seldom used. We are developing a single subcutaneous catheter that serves both as a CGM and as an insulin cannula. The electrodes and chemicals necessary for CGM are disposed on the outer wall of the cannula. Based on recent animal studies, we now know that the electroactivity of insulin preservatives is incompatible with conventional amperometric sensing technology. In order to minimize interference from these preservatives after bolus delivery, we will work with an organic chemist to identify sensing chemistries that allow detection of glucose oxidation at low redox potentials, where the preservatives have minimal to no electroactivity. The chemistry will either be (a) a redox mediator coordinated within a pyridine or imidazole-based ligand or (b) a horseradish peroxidase-based system designed to measure reduction of H2O2 at negative potentials. Electrochemical screening will take place using solution phase cyclic voltammetry. The chemistry will be optimized to immobilize sensing layers and create a durable sensor: The most promising compounds will be immobilized on Au or Pt indicating electrodes followed by crosslinking to glucose oxidase. The final choice of solid phase chemistry will be based in large part on maximizing the glucose:cresol response ratio, ensuring stable function for at least 4 days, and avoidance of leaching. If a redox mediator is chosen, the outer membrane will be selected to have very low permeability to oxygen due to the fact that oxygen competes with redox mediators. An existing permeation cell will be used to measure oxygen and glucose membrane permeability. In Yucatan pigs, we will assess preservative interference during insulin delivery 1- and 4 days after sensor insertion. The purpose of the second study at 4 days is to determine if sensor sensitivity declines over this period, which would suggest loss of reagents from the sensor. In summary, to minimize device burden in T1D, we will develop and test a sensing chemistry that avoids the large interference one sees from preservatives during insulin boluses, thus allowing CGM and insulin delivery via a single catheter.

Public Health Relevance Statement:


Public Health Relevance:
In this project, a dual-use catheter will be developed and tested in pigs. The outer wall of this device will be used to continuously monitor glucose and the inner lumen will be a conduit through which insulin will be continuously infused. The successful development of such a device would benefit Type 1 diabetes (T1D) patients, who are at high risk for disease of the eyes, kidneys, nerves, feet and cardiovascular system. Despite the known efficacy of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM), less than 5% of people in the US with T1D use both technologies concurrently. This failure can be explained in large part by the inconvenience and body image threat from using two percutaneous ("through the skin") devices. Currently available glucose sensors are not able to measure glucose at the site of insulin delivery because the preservatives in insulin cause major interference in the glucose measurement. In this project, an alternative chemistry that avoids the preservative-induced interference will be developed. To the extent that the two functions can be combined into a single unified catheter, it is likely that the concurrent usage of CGM and CSII would increase substantially. This increased usage would be expected to reduce the incidence of acute and chronic diabetes complications.

Project Terms:
Acute; Animals; base; Body Image; Bolus Infusion; Cannulas; Cardiovascular system; Catheters; Cell Membrane Permeability; Cells; Chemicals; Chemistry; Chronic; Complications of Diabetes Mellitus; Continuous Infusion; Control Groups; Cresol; crosslink; design; Detection; Development; Devices; Dose; Electrodes; electron donor; Electrons; Electrostatics; Ensure; Eye diseases; Failure; Family suidae; foot; Glucose; glucose monitor; glucose oxidase; glucose sensor; Goals; high risk; Horseradish Peroxidase; Hydrogen Peroxide; Hyperglycemia; Imidazole; Incidence; Inductively Coupled Plasma Mass Spectrometry; Infusion procedures; Insulin; Insulin-Dependent Diabetes Mellitus; Kidney; Ligands; Liquid substance; Measurement; Measures; Mediator of activation protein; Membrane; Metals; Methods; Nerve; non-diabetic; Nylons; Osmium; oxidation; Oxidation-Reduction; Oxygen; Patients; Permeability; Peroxides; Phase; Phenols; Polyesters; Polyurethanes; public health relevance; pyridine; Reagent; response; Saline; screening; sensor; Signal Transduction; Silicones; Site; Skin; Solid; subcutaneous; System; Technology; terephthalate; Testing; Urethane; Work

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
----
Phase II Amount
----